Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 12, 2001, Pages 3304-3309

  Martinez, A ^a   Ferrer, S ^a   Santos, I ^a   Jimenez, E ^a   Sparrowe, J ^a   Regadera, J ^a   Gomez de las Heras, F ^a   Gargallo Viola, D ^a  

^a GLAXOSMITHKLINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FUNGAL PROTEIN; GW 471552; GW 471558; SORDARIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; IMMUNE DEFICIENCY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; THRUSH; VAGINA CANDIDIASIS;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CANDIDA ALBICANS; CANDIDIASIS, ORAL; CANDIDIASIS, VULVOVAGINAL; COLONY COUNT, MICROBIAL; DEXAMETHASONE; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INDENES; MICROBIAL SENSITIVITY TESTS; MORPHOLINES; RATS; RATS, SPRAGUE-DAWLEY; TONGUE;

EID: 0035185184     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.12.3304-3309.2001     Document Type: Article

References (22)

1. Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM237354) in a murine model of lethal candidiasis
2. Efficacies of sordarin derivatives GM193663, GM211676, or GM237354 in a murine model of systemic coccidioidomycosis
3. Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for candida vaginitis
4. Comparison of four molecular typing methods for evaluating genetic diversity among Candida albicans isolates from human immunodeficiency virus-positive patients with oral candidiasis
5. Sordarins: A new class of antifungal with selective inhibition of the protein synthesis elongation cycle in yeast
6. Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans
7. Sordarins as antifungical compounds
8. Control of Candida albicans murine vaginitis by topical administration of polycarbophil-econazole complex
9. Activities of sordarins in murine histoplasmosis
10. Antifungal activities and cytotoxicity studies of six new azasordarins
11. Sordarins: In vitro activities of new antifungal derivatives against pathogenic yeast, Pneumocystis carinii, and filamentous fungi
12. Experimentally induced acute oral candidosis in the rat
13. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients
14. Activities of sordarins in experimental models of candidiasis, aspergillosis, and pneumocystosis
15. Antifungal efficacy of GM237354, a sordarin derivative, in experimental oral candidiasis in immunosuppressed rats
16. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in human immunodeficiency virus-infected patients
17. Experimental oral candidiasis in animal models
18. Current and emerging azole antifungal agents
19. Selected animal models: Vaginal candidosis, pneumocystosis pneumonia, dermatophytosis and trichosporonosis
20. Comparison of ketoconazole (BAY L9139) in the treatment of experimental vaginal candidiasis
21. Experimental chronic vaginal candidosis in rats